This playbook examines how early-phase biotech companies operating under constraints can use integrated development models to improve continuity.
Many early-stage biotech companies are advancing innovative science under intense pressure to move quickly, conserve capital, and demonstrate value—often with lean teams and limited internal infrastructure. The challenge is no longer scientific ambition alone. It is the ability to make high-stakes development decisions early—often before an IND is submitted—when visibility into downstream implications is limited and the margin for error is narrow.
Decisions made at this stage increasingly determine not just whether a program advances into the clinic, but whether it remains viable through later phases. This playbook examines how early-phase biotech companies operating in an environment of constraint can use integrated development models to improve continuity. It shows how these companies can:
- Reframe early development decisions to reduce downstream risk
- Identify where early complexity undermines momentum
- Evaluate connected development approaches for long-term value
Offered Free by: BioPharma Dive’s Studio by Informa TechTarget and ThermoFisher
See All Resources from: BioPharma Dive’s Studio by Informa TechTarget and ThermoFisher
